Photo by ozgomz from unsplash
Empagliflozin treatment reduced liver fat in small type 2 diabetes cohorts. This post‐hoc study evaluated effects of empagliflozin on risk for non‐alcoholic fatty liver disease‐related steatosis and fibrosis, as well… Click to show full abstract
Empagliflozin treatment reduced liver fat in small type 2 diabetes cohorts. This post‐hoc study evaluated effects of empagliflozin on risk for non‐alcoholic fatty liver disease‐related steatosis and fibrosis, as well as the relationship between risk categories and cardiorenal outcomes in the randomized, placebo‐controlled EMPA‐REG OUTCOME trial.
Keywords:
empagliflozin markers;
relationship;
cardiorenal outcomes;
steatosis fibrosis;
effects empagliflozin
Journal Title: Diabetes
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Diabetes
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!